Streetbeat News

Products Services

DOGEUSD

Dogecoin (DOGE) experienced a 6% increase over the past week, with a video hinting at DOGE payments on X and suggestions from an analyst to short DOGE between $0.18 and $0.20. The video featured Elon Musk and implied the integration of Dogecoin as a payment method on X, Tesla, and SpaceX. However, analyst CrediBULL Crypto plans to short Dogecoin, predicting a drop to $0.04 to $0.05 as Bitcoin approaches $100,000. DOGE's large transaction volume and daily active addresses have also seen significant increases.

Portfolio Pulse from Khyathi Dalal

April 23, 2024 | 6:24 pm

NVS

Novartis has received FDA approval for Lutathera, the first medicine specifically designed for pediatric patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The approval is based on the NETTER-P trial, which showed Lutathera has a consistent safety profile and comparable drug exposure between pediatric and adult patients. GEP-NETs are a rare, often late-diagnosed cancer. Novartis is expanding its radioligand therapy portfolio to treat various cancers, including lung, prostate, breast, and more.

Portfolio Pulse from Benzinga Newsdesk

April 23, 2024 | 6:15 pm

META

Meta Platforms Inc (NASDAQ:META) is set to report its Q1 earnings with high expectations from analysts, projecting a significant year-over-year revenue and EPS increase. Analysts anticipate a challenging quarter ahead due to tougher YoY comparisons, European regulations, and the impact of China-based advertisers. The company's advancements in AI and potential for a 'first mover advantage' in generative AI are highlighted as key factors to watch. Shares of META have seen a substantial increase, up over 130% in the last year.

Portfolio Pulse from Chris Katje

April 23, 2024 | 6:13 pm

EA

TTWO

Electronic Arts Inc. (NASDAQ:EA) is set to report its F4Q earnings on May 7, with expectations moderated due to macroeconomic challenges and a conservative outlook on live service bookings and game releases. Analysts from Oppenheimer, Martin Yang and Andrew Northcutt, maintain an Outperform rating on EA with a $150 price target, citing decent downside protection despite market challenges. The report anticipates strategic discussions on EA's digital and mobile growth, new game launches, and potential for strategic mergers and acquisitions. EA's stock was trading at $127.50, showing a slight increase. The analysts also compare EA favorably to Take-Two Interactive Software Inc (NASDAQ:TTWO), suggesting EA as a better buy in the near term.

Portfolio Pulse from Franca Quarneti

April 23, 2024 | 5:47 pm

BRKR

DHR

MEDP

Bruker Corporation's stock is trading higher due to positive momentum in the life sciences tools sector, influenced by strong earnings reported by Danaher and optimistic guidance from Medpace.

Portfolio Pulse from Benzinga Newsdesk

April 23, 2024 | 5:37 pm

COPP

CRIT

FCX

Freeport-McMoRan Inc. (NYSE:FCX) reported first-quarter FY24 results with revenue of $6.32 billion and adjusted EPS of $0.32, both surpassing consensus estimates. Copper and gold sales increased significantly, with operating income and cash flow showing improvement. The company provided positive outlooks for Q2 FY24 and the full year, expecting strong sales volumes and operating cash flows. Despite the positive results and outlook, FCX shares are trading lower. Exposure to FCX can be gained through Sprott Copper Miners ETF (NASDAQ:COPP) and Exchange Traded Concepts Trust Optica Rare Earths & Critical Materials ETF (NYSE:CRIT).

Portfolio Pulse from Lekha Gupta

April 23, 2024 | 5:35 pm

META

Elon Musk's social media platform X, formerly Twitter, announced the launch of the X TV App, aiming to offer real-time, engaging content on smart TVs. CEO Linda Yaccarino highlighted the app's focus on a high-quality, immersive entertainment experience. The app will allow for a cross-device experience and personalized video organization. Musk criticized Meta Inc.'s Instagram, particularly for its logo watermark on Reels. Hyundai halted its advertising on X due to the appearance of pro-Nazi content, and Pakistan blocked access to X citing national security concerns.

Portfolio Pulse from Lekha Gupta

April 23, 2024 | 5:30 pm

NBIX

TAK

Neurocrine Biosciences Inc (NASDAQ:NBIX) announced positive Phase 2 results for NBI-1065845, a treatment for major depressive disorder (MDD), developed in collaboration with Takeda Pharmaceutical Company Limited (NYSE:TAK). The study met its primary and key secondary endpoints, showing significant improvement in depression scores. The treatment was well tolerated, with headache being the most common adverse event. William Blair maintains an Outperform rating on Neurocrine, highlighting the potential for significant sales and the importance of Ingrezza revenue.

Portfolio Pulse from Vandana Singh

April 23, 2024 | 5:28 pm

ZM

Columbia University is reportedly considering moving classes to remote learning for the rest of the year due to protests. This development is being closely watched by investors in Zoom Video Communications (ZM), as it could potentially increase the demand for Zoom's services.

Portfolio Pulse from Benzinga Newsdesk

April 23, 2024 | 5:27 pm

ZM

Columbia University President Minouche Shafik announced that classes will be held virtually due to protests, impacting the use of Zoom (ZM) for remote education.

Portfolio Pulse from Benzinga Newsdesk

April 23, 2024 | 5:26 pm